As Klf15 is part of the GC-GR-KLF15-BCAA pathway, previously shown to be dysregulated in SMA muscle, it is possible that mifepristone treatment in animal models or SMA patients may modulate BCAA levels. This evidence concerns the gene NR3C1 and proximal spinal muscular atrophy.